SCHEMBL14980282

SCHEMBL14980282

CN1CCN(Cc2ccnc3ccccc23)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.69
KDM4E B2RXH2 3/20 0.69
ALDH1A1 P00352 2/20 0.69
NPSR1 Q6W5P4 2/20 0.69
LMNA P02545 1/20 0.69
FAAH O00519 1/20 0.57
HTR6 P50406 2/20 0.52
METAP2 P50579 1/20 0.52
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPT P10636 2/20 0.49
GAA P10253 1/20 0.49
LOXL2 Q9Y4K0 1/20 0.49
MC4R P32245 1/20 0.49
HTR1A P08908 1/20 0.48
HTR1D P28221 1/20 0.48
HTR1B P28222 1/20 0.48
ADRA2A P08913 1/20 0.48
ADRA2B P18089 1/20 0.48
ADRA2C P18825 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23507365 0.85 KDM4E (0.70) SMN1; SMN2KDM4EALDH1A1NPSR1LMNA
SCHEMBL23775340 0.85 KDM4E (0.66) SMN1; SMN2KDM4EALDH1A1NPSR1LMNA
SCHEMBL807235 0.84 KDM4E (0.68) SMN1; SMN2KDM4EALDH1A1NPSR1LMNA
SCHEMBL31010255 0.84 KDM4E (0.68) SMN1; SMN2KDM4EALDH1A1NPSR1LMNA
SCHEMBL19464760 0.84 ALDH1A1 (0.64) SMN1; SMN2KDM4EALDH1A1NPSR1LMNA
SCHEMBL16219451 0.84 KDM4E (0.64) SMN1; SMN2KDM4EALDH1A1NPSR1LMNA
SCHEMBL14375211 0.82 ACHE (0.62) SMN1; SMN2KDM4EALDH1A1NPSR1LMNA
SCHEMBL3707217 0.81 LMNA (0.65) SMN1; SMN2KDM4EALDH1A1NPSR1LMNA
SCHEMBL31428721 0.81 ALDH1A1 (0.69) SMN1; SMN2KDM4EALDH1A1NPSR1LMNA
SCHEMBL3705464 0.80 ALDH1A1 (0.63) SMN1; SMN2KDM4EALDH1A1NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790499-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9278987-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2016-03-08 US disclosed
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2014-11-06 US disclosed
WO-2013074834-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF RTCB, NSUN3, NSUN2 SMN1; SMN2 203/4885KDM4E 3565/4885ALDH1A1 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.